logo
FICO European Fraud Map: UK Leads in 'Card Not Present' Fraud and Total Losses

FICO European Fraud Map: UK Leads in 'Card Not Present' Fraud and Total Losses

Globe and Mail16-07-2025
The FICO European Fraud Map 2024 has revealed a worrying trend of rising card fraud levels and losses across the continent. The data from Euromonitor International on 18 countries shows that Card Not Present (CNP) fraud dominates card fraud losses and has increased across most countries. E-commerce fraud, e-wallet, social engineering and QR code fraud or 'quishing' are all rising as well.
More information: https://www.fico.com/en/europeanfraud
Highlights
Card fraud losses across EMEA have increased from €1,493m in 2021 to €1,578m in 2024
UK card fraud increased by 4% to £572.6 million since 2023
CNP fraud accounts for around 70% of total card fraud losses in the UK – increasing by 11% year on year
Hungary saw the greatest increase across Europe at 22% — card fraud losses also dramatically increased in Norway, Denmark and Hungary
Portugal and the Netherlands are the only countries to see fraud levels fall
'While card fraud loss figures are still lower than the 2015 peak of €1,642 million, the last few years show that fraud in Europe is steadily rising back up towards this figure,' commented James Roche, principal fraud consultant for FICO in EMEA. 'The UK has followed a similar trajectory to the rest of Europe, aligning with what FICO has seen in terms of the dominant fraud MOs that plague both the UK and Europe, as well as the common approaches taken in the last decade via initiatives such as PSD and PSR.'
Card Losses Grow in UK
In 2024, UK Finance reported £572.6 million in total card fraud losses, a 3.9% increase from £551.3 million in 2023. This goes against the trend of the past few years of falling card losses and a broader trend of stabilisation in the UK payments landscape, which is a cause for concern.
Card Not Present (CNP) fraud remained the leading fraud category, accounting for around 70% of total card fraud losses. This marks an increase of 11% from 2023 and puts the UK at the top of the league table for CNP fraud losses in Europe, underscoring the persistent risk associated with remote transactions.
Conversely, identity (ID) fraud losses dropped significantly by 26% to £58.7M, pointing to a shift in criminal behaviour away from ID theft and towards social engineering, data compromises and scams. The growing use of fraud enhancements such as biometric and behavioural monitoring tools are also likely to have contributed to the decrease. Plus, continued investment by UK and EU financial services in full customer journey visibility and data sharing is enabling identity characteristics to be monitored from onboarding through early book and ongoing lifecycle stages of the customer journey.
'The UK has long been a leader in deploying innovative fraud technology, and clearly the challenges are still growing,' Roche said. 'With PSD3 regulations now taking effect across Europe, we see fraud prevention teams moving towards a unified approach to fraud risk assessment. Continued investment in preventative tools, such as Scam Signal, and intelligence-led fraud detection remain critical to protecting card portfolios from evolving threats.'
The Picture across Europe
Other highlights from the FICO European Fraud Map show the impact card fraud is having across the region :
In Norway fraud losses have dramatically increased over the last few years from €14M in 2021 to €26.4M, rising 8% in 2024.
Denmark demonstrated a more than twofold increase in fraud losses (€19.6M to €47.6M) since 2021, and a concerning 20% rise in 2024 alone.
In Hungary, fraud losses jumped from €3.3M to €22.4M from 2021 to 2024, rising by 22% in 2024.
Greece has also seen a significant increase, with a twofold increase from €13.4M to €28.4M since 2021 and 20% in 2024.
Sweden's losses have risen significantly from €13.1M to €24.2M, an increase of around 85% in three years, and 19% during 2024.
Despite the overall EMEA loss picture trending slowly upwards, a few countries are seeing a downward trend in their card fraud losses:
France's losses are slowly but steadily decreasing and have done so consistently since their peak at €433.2M in 2018. They now sit at €409.2M, the second highest losses of the 18 countries studied but setting a good example for controlling their losses.
Turkey showed significantly lower losses at €1.1M for 2024, but they too are reducing their fraud losses consistently and have done since their peak at €14M in 2010. However, 2024 saw fraud rise by 5% in Turkey.
'With PSD3 regulations due to take effect across Europe in the next couple of years, financial institutions must work harder than ever to fight new fraud patterns and improve customer service,' said Roche. 'We are seeing a number of emerging approaches that unify protection that is currently siloed, using 360-degree customer profiling to assess fraud and financial crime risk across all channels and products and throughout the entire lifecycle of the customer (onboarding through to offboarding). We at FICO believe this approach is absolutely critical, as criminals look for the weakest link in fraud defences.'
FICO's fraud solutions portfolio includes the AI-powered FICO ® Falcon ® Fraud Manager , which protects more than 4 billion cards worldwide; FICO ® Omni-Channel Communications for Fraud , available on FICO® Platform; and award-winning models for scam detection, as well as the award-winning Scam Signal product developed with Jersey Telecom.
About FICO
FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting 4 billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency. Learn more at www.fico.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FTase Inhibitor Market Set for Significant Growth Through 2034, Driven by Oncology and Rare Disease Applications
FTase Inhibitor Market Set for Significant Growth Through 2034, Driven by Oncology and Rare Disease Applications

Globe and Mail

time15 minutes ago

  • Globe and Mail

FTase Inhibitor Market Set for Significant Growth Through 2034, Driven by Oncology and Rare Disease Applications

DelveInsight projects strong FTase inhibitors market growth through 2034, led by oncology and rare disease use. Key companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), Novartis (alpelisib combos), Eiger BioPharmaceuticals, and AnGes Inc. Advances target progeroid laminopathies, HRAS-mutant HNSCC, and novel indications, with approvals, partnerships, and late-stage trials driving expansion. DelveInsight's ' FTase Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 ' report delivers a comprehensive analysis of the FTase Inhibitor market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of FTase inhibitors in the 7MM is expected to surge significantly by 2034, driven by expanding applications in oncology and rare genetic disorders. Patient population data: The report provides the total FTase inhibitor potential pool, including Progeria cases occurring in approximately 1 in every 4 million live births worldwide and around 900K new head and neck squamous cell carcinoma cases each year. Key companies: Leading FTase inhibitor companies, such as Sentynl Therapeutics (formerly Eiger BioPharmaceuticals), Kura Oncology, and others are profiled. FTase Inhibitors Pipeline assets: Some of the key FTase inhibitor pipeline assets include tipifarnib in HRAS-mutant HNSCC and novel combination regimens with PI3Kα inhibitors. In March 2025, significant study published research on the highly active FTase peptide inhibitor PD083176 (d2,d3,d5) for treating acute liver failure (ALF), demonstrating that this optimized FTase inhibitor could attenuate ALF progression by modulating PANoptosis. Another research puslished in January 2025 demonstrated that lonafarnib (LNF), an approved oral FTase inhibitor, shows promise as an antiviral treatment against SARS-CoV-2. January 2024: ZOKINVY (lonafarnib) secured marketing approval in Japan via Eiger BioPharmaceuticals and partner AnGes Inc. May 2024: Sentynl Therapeutics closed the acquisition of the ZOKINVY program from Eiger BioPharmaceuticals. Discover recent advancements in the FTase Inhibitor landscape @ FTase Inhibitor Recent Developments. FTase Inhibitors Market Dynamics The FTase inhibitors market currently represents a niche yet high-growth segment within targeted therapeutics. As of 2025, the market remains modest in size, primarily anchored by ZOKINVY's orphan-disease indications, but is poised for expansion through oncology applications. FTase Inhibitors market momentum is propelled by validated survival benefits in ultra-rare progeroid laminopathies and emerging data in HRAS-driven cancers. Scientific rationale for FTase inhibition stems from the blockade of protein farnesylation, notably of progerin in HGPS and HRAS in HNSCC, disrupting aberrant cell signaling and proliferation. The FTase Inhibitors clinical development activity is robust, with tipifarnib advancing through Phase II/III trials both as monotherapy and in combination with Novartis's alpelisib. Additional early-stage candidates are exploring synergistic strategies to overcome resistance via dual prenylation pathway targeting. The FTase Inhibitor competitive landscape features established biotech players, with strategic alliances and licensing deals facilitating access to novel mechanisms and patient populations. For example, the Sentynl–AnGes partnership accelerated ZOKINVY's geographic reach, while Kura Oncology's collaborations underpin its oncology pipeline. FTase Inhibitors market barriers include compensatory prenylation pathways (geranylgeranylation) that may attenuate FTase inhibitor efficacy, and the ultra-orphan status limiting commercial scale. However, opportunities abound in biomarker-driven patient selection, combination regimens to deepen responses, and expansion into other RAS-dependent malignancies. Future outlook is characterized by anticipated label extensions, pipeline maturation, and reimbursement shifts as payers recognize the value of targeted disruption of oncogenic and progeroid pathways. Download the FTase Inhibitor Market report to understand which factors are driving the therapeutic market @ FTase Inhibitor Market Trends. FTase Inhibitors Targeted Patient Pool FTase inhibitors address indications such as progeroid laminopathies and head and neck squamous cell carcinoma. Epidemiology segmentation reveals that Hutchinson-Gilford Progeria Syndrome occurs in approximately 1 in 4 million live births, yielding around 400 affected children and young adults globally. Conversely, HNSCC accounts for roughly 890,000 new cases and 450,000 deaths annually worldwide. The total eligible patient pool for FTase inhibitors thus spans ultra-rare genetic disease patients and a subset of HRAS-mutant HNSCC. Real-world treated cases remain limited in progeria due to recent approvals, whereas oncology uptake is emerging in biomarker-enriched cohorts. Geographic segmentation shows the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan as primary markets, with forecasted growth over the 2020–2034 period driven by regulatory approvals, improved diagnostics, and expanded trial enrollment. Discover evolving trends in the FTase Inhibitor patient pool forecasts @ FTase Inhibitor Patient Pool Analysis. Key FTase Inhibitors Companies and Treatment Market The FTase inhibitors treatment landscape is anchored by ZOKINVY (lonafarnib), the first FDA-approved therapy for HGPS and processing-deficient progeroid laminopathies, now commercialized by Sentynl Therapeutics. Current treatment options for progeria are limited to lonafarnib, supplemented by supportive care measures. In oncology, no FTase inhibitor is yet approved, but tipifarnib (Kura Oncology) is in late-stage trials for HRAS-mutant HNSCC, both as monotherapy and in combination with alpelisib. Key FTase Inhibitors companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), and strategic collaborators like Novartis (alpelisib combinations) and AnGes Inc. (Japan licensing). Market positioning for FTase inhibitors hinges on their unique mechanism of action, blocking prenylation to impair oncogenic signaling and progerin accumulation. Development milestones encompass ZOKINVY's 2020 FDA approval, its January 2024 Japanese approval, and its May 2024 acquisition by Sentynl. Kura Oncology's tipifarnib recently reported promising Phase II responses in HRAS-driven cohorts, earning Breakthrough Therapy Designation in select indications. Commercial arrangements include licensing of lonafarnib in Asia and co-development agreements for oncology combinations, underscoring the collaborative strategies propelling the FTase inhibitors market forward. Delve deeper into the major and specialised companies in the FTase Inhibitor market @ FTase Inhibitor Competitive Landscape. Conclusion The FTase inhibitors market is at an inflection point, transitioning from a rare-disease focus to broader oncology applications. With established clinical benefits, a robust pipeline, and strategic partnerships, FTase inhibitors are set to redefine treatment paradigms for progeroid disorders and HRAS-driven cancers through 2034 and beyond. Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary of FTase Inhibitor 4. Key Events 5. FTase Inhibitor Epidemiology Market Forecast Methodology 6. FTase Inhibitor Market Overview at a Glance in the 7MM 7. FTase Inhibitor: Background and Overview 8. Epidemiology and FTase Inhibitor Patient Population in Different Indications 9. FTase Inhibitor Target Patient Pool 10. FTase Inhibitor Marketed Therapies 11. FTase Inhibitor Emerging Therapies 12. FTase Inhibitor: Seven Major Market Analysis 13. FTase Inhibitor SWOT Analysis 14. KOL Views 15. FTase Inhibitor Unmet Needs 16. Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:

Gunshot heard downtown London, police investigating
Gunshot heard downtown London, police investigating

CTV News

timean hour ago

  • CTV News

Gunshot heard downtown London, police investigating

A gunshot was fired downtown London on Tuesday night, according to police. At approximately 10 p.m., police responded to the report of a gunshot at the intersection of Dundas and English Streets. Evidence was allegedly found of a gunshot in the area. No injuries or damages have been reported, and no weapon was found. The investigation is ongoing, and police are asking anyone who was in the area between 9:45 p.m. to 10:15 p.m. to reach out with relevant information or surveillance footage.

NIKE Bets on EMEA Growth: Can This Strategy Pay Off in FY26?
NIKE Bets on EMEA Growth: Can This Strategy Pay Off in FY26?

Globe and Mail

time3 hours ago

  • Globe and Mail

NIKE Bets on EMEA Growth: Can This Strategy Pay Off in FY26?

NIKE Inc. 's NKE EMEA strategy is emerging as one of the most promising growth levers for fiscal 2026, building on progress already made in cleaning up the marketplace and repositioning NIKE Digital as part of an integrated channel strategy. In fourth-quarter fiscal 2025, the region delivered growth in key performance categories like running and training, while women's sportswear footwear returned to growth. Wholesale sportswear also posted gains, reflecting the benefits of diversifying beyond classic franchises such as Air Force 1, Dunk and AJ1. The company ended the quarter with inventory slightly ahead of targets and a healthier balance of full-price sales. A core pillar of NIKE's EMEA push is the 'sport offense' realignment, dedicated cross-functional teams focused on specific sports to deepen athlete relationships, drive targeted innovation and tailor storytelling by market. This sharper focus enables the company to match local consumer demand with sport-specific product pipelines, such as high-performing running footwear (led by the Vomero 18 franchise) and expanded women's basketball offerings. The approach also supports sharper marketplace segmentation, allowing NIKE to deliver unique assortments to wholesale partners like JD Sports while maintaining premium positioning in NIKE Direct. In fiscal 2026, NIKE expects the EMEA region to benefit from a stronger holiday order book, bolstered by growth in performance categories and new dimensions in sportswear to offset declines in classic franchises. Momentum in the region is also supported by improved wholesale sell-through rates, healthier inventory levels and higher full-price sales penetration. If the sport offense model continues to generate both consumer excitement and channel profitability, EMEA could be a key driver of the company's return to sustainable growth in fiscal 2026. NKE's Competition in the Global Arena adidas AG ADDYY and lululemon athletica inc. LULU are the key companies competing with NIKE in the global market. adidas remains one of NIKE's strongest global competitors, leveraging its deep heritage in performance sports and lifestyle segments to maintain a strong foothold in markets like EMEA and Asia-Pacific. The brand continues to benefit from its credibility in football, running and training, reinforced by partnerships with elite clubs, athletes and cultural icons. In recent years, adidas has accelerated its innovation cycle, introducing performance-driven footwear like the Adizero and Ultraboost lines, while expanding its sustainability initiatives, such as increasing the use of recycled materials through its Primegreen and Primeblue platforms. lululemon has carved out a premium niche in athletic apparel, dominating the global yoga, studio and athleisure markets while steadily expanding into high-performance categories like running, training, golf and tennis. lululemon's vertically integrated model, with a strong direct-to-consumer foundation, allows for tight control over pricing, product drops and customer experience. NKE's Price Performance, Valuation & Estimates Shares of NIKE have lost 1.1% year to date compared with the industry 's decline of 5.2%. From a valuation standpoint, NKE trades at a forward price-to-earnings ratio of 40.07X compared with the industry's average of 29.34X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for NKE's fiscal 2025 earnings implies a year-over-year decline of 12.04%, while that for fiscal 2026 indicates growth of 1.9%. The company's EPS estimate for fiscal 2025 and 2026 has been unchanged in the past seven days. Image Source: Zacks Investment Research NIKE currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIKE, Inc. (NKE): Free Stock Analysis Report lululemon athletica inc. (LULU): Free Stock Analysis Report Adidas AG (ADDYY): Free Stock Analysis Report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store